89bio Statistics
Share Statistics
89bio has 117.58M shares outstanding. The number of shares has increased by 25.75% in one year.
| Shares Outstanding | 117.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 11.02% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 112.63M |
| Failed to Deliver (FTD) Shares | 6 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 6.94M, so 5.9% of the outstanding shares have been sold short.
| Short Interest | 6.94M |
| Short % of Shares Out | 5.9% |
| Short % of Float | 6.16% |
| Short Ratio (days to cover) | 6.7 |
Valuation Ratios
The PE ratio is -5.59 and the forward PE ratio is -3.15.
| PE Ratio | -5.59 |
| Forward PE | -3.15 |
| PS Ratio | 0 |
| Forward PS | 24.8 |
| PB Ratio | 1.48 |
| P/FCF Ratio | -6.15 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for 89bio Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.04, with a Debt / Equity ratio of 0.05.
| Current Ratio | 20.04 |
| Quick Ratio | 20.04 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 4.81 |
| Cash Flow / Debt | -4.77 |
| Interest Coverage | -42.17 |
Financial Efficiency
Return on equity (ROE) is -0.27% and return on capital (ROIC) is -27.59%.
| Return on Equity (ROE) | -0.27% |
| Return on Assets (ROA) | -0.24% |
| Return on Capital (ROIC) | -27.59% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.03M |
| Employee Count | 70 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 3.87M |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by -43.27% in the last 52 weeks. The beta is 0.98, so 89bio 's price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | -43.27% |
| 50-Day Moving Average | 8.27 |
| 200-Day Moving Average | 8.48 |
| Relative Strength Index (RSI) | 27.65 |
| Average Volume (20 Days) | 975.55K |
Income Statement
| Revenue | n/a |
| Gross Profit | -273.00K |
| Operating Income | -151.20M |
| Net Income | -142.19M |
| EBITDA | -134.46M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2 |
Balance Sheet
The company has 316.16M in cash and 27.11M in debt, giving a net cash position of 289.05M.
| Cash & Cash Equivalents | 316.16M |
| Total Debt | 27.11M |
| Net Cash | 289.05M |
| Retained Earnings | -457.43M |
| Total Assets | 458.30M |
| Working Capital | 417.07M |
Cash Flow
In the last 12 months, operating cash flow was -129.19M and capital expenditures -4.00K, giving a free cash flow of -129.19M.
| Operating Cash Flow | -129.19M |
| Capital Expenditures | -4.00K |
| Free Cash Flow | -129.19M |
| FCF Per Share | -1.82 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ETNB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -31.85% |
| FCF Yield | -17.5% |
Analyst Forecast
The average price target for ETNB is $29.5, which is 369.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $29.5 |
| Price Target Difference | 369.7% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 3.92 |
| Piotroski F-Score | 2 |